| INCYTE DL-,001 | 65.42 / +0.28% |
| Date/Time | 07/30 / 18:42 |
| Chg. / Chg.(%) | 0.18 / +0.28% |
| Bid | - |
| Ask | - |
| Open | 64.76 |
| Previous Close | 65.24 |
| High | 65.42 |
| Low | 64.66 |
| Volume [EUR] | 0.00 |
| Volume [Units] | 0 |
| Price fixings | 15 |
| ISIN | US45337C1027 |
| Security | ICY |
| Exchange | Berlin |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| NASDAQ | 77.3500 |  |
1,486,796 |
| IEX | 77.32 | |
59,316 |
| Cboe US | 77.38 | |
55,940 |
| TradeGate | 65.300 | |
65 |
| Moscow | 5,681.00 | |
64 |
| Frankfurt | 64.4800 |  |
0 |
| München | 65.18 | |
0 |
| Düsseldorf | 65.46 | |
0 |
| Berlin | 65.42 | |
0 |
| Stuttgart | 65.220 | |
0 |
| Lang & Schwa.. | 65.00 | |
|
| London Inter.. | 77.74 | |
|
| Quotrix | 64.9600 | |
|
| gettex | 65.300 | |
|
| Mexico | 1,748.35 |  |
900 |
News
- MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results
07/29/2021 / 22:01 - GlobeNewswire - Merus Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation
07/21/2021 / 14:00 - GlobeNewswire - BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment
07/14/2021 / 13:22 - GlobeNewswire - First Patient Dosed in Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion
06/18/2021 / 02:00 - GlobeNewswire - AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
06/07/2021 / 02:00 - GlobeNewswire
Real-time